Inrobics, a technology company spun out of Universidad Carlos III de Madrid and specialising in social artificial intelligence for healthcare, has launched a new funding round through Startupxplore, the Spanish startup co-investment platform. The round is backed by Grow Venture Partners, a venture capital fund specialising in deeptech and technology transfer, as lead investor with a €250,000 commitment.
The company aims to raise between €520,000 and €750,000, of which more than €485,000 has already been committed, placing the round at over 64% of its minimum target. The investment will be structured through a special purpose investment vehicle (SPV), which will be incorporated once the round has been successfully completed.
Alma: A Modular, Hardware-Agnostic Social AI Platform
Inrobics has developed Alma, its proprietary modular and multimodal artificial intelligence platform, designed to integrate seamlessly with social robots, tablets and virtual assistants without relying on any specific hardware. The platform supports, motivates and guides users throughout therapeutic, educational and cognitive stimulation programmes, adapting activities in real time while generating objective performance metrics for healthcare and education professionals.
The company was founded to address one of the most pressing challenges facing healthcare and long-term care systems: expanding care capacity in the face of an ageing population and a growing shortage of professionals, without increasing workloads or operating costs.
Today, Inrobics operates across three core business areas:
More Than a Decade of Research and Clinical Validation
Following more than ten years of research and development, Inrobics has successfully overcome technological risk and entered its commercial scaling phase. The company has already generated more than €500,000 in revenue, deployed its technology across more than 20 healthcare and educational centres, and supported over 1,000 users in clinical, educational and social care environments.
In addition, Inrobics has secured more than €800,000 in contracted revenue for 2026 and maintains an active commercial pipeline exceeding €12 million, including projects in special education, nursing homes and home care services. Clinical results include therapy adherence rates above 95% and a reduction of up to 90% in the time professionals spend on repetitive tasks.
The technology is CE-marked as medical software, operates under processes aligned with ISO 13485, complies with the General Data Protection Regulation (GDPR) and is progressing towards FDA certification. The company is also supported by technology and services partners including Telefónica and Inetum, and has been recognised by programmes such as RETECH Comunidad de Madrid, UNICEF Lab, Lilly Emprende inHealth, CaixaImpulse, Mobile World Capital – The Collider, and Fundación ONCE, among others.
Lead Investor's Perspective
Grow Venture Partners, the Barcelona-based venture capital fund specialising in scientific and technology spin-offs originating from universities and research centres, has highlighted Inrobics' scalability and its potential to become a core technology platform for healthcare, rehabilitation and active ageing.
According to the fund, the company combines exposure to a structural market opportunity—the widening gap between the growing demand for care services and the availability of qualified professionals—with strong commercial validation, supported by more than a decade of technological development, successful deployments in real-world environments and an expanding commercial pipeline involving public institutions and major healthcare and social care providers.
Grow Venture Partners typically invests at the pre-seed and seed stages, with investment tickets ranging from €100,000 to €2 million. The firm has more than 20 years of experience, has reviewed over 5,000 business plans, and has completed 21 investments to date.
Further details about the funding round and information on how to participate are available through theStartupxplore investment page.
cloud technology axon
During the session, the company presented details of its investment po...
